Press Releases

“Multiple myeloma (MM), the second most common hematologic malignancy in the United States, has undergone transformative therapeutic innovation over the past five decades.”

BUFFALO, NY – April 29, 2026 – A new research paper was published in Volume 17 of Oncotarget on April 28, 2026, titled “Targeted therapeutics and U.S. population-level mortality trends in multiple myeloma: A SEER-based analysis from 1975 to 2023.”

The study was led by first and corresponding author Navkirat Kahlon from... Mass General Cancer Center at Wentworth-Douglass Hospital, in collaboration with researchers from multiple U.S. institutions. In this study, the researchers examined how mortality trends in multiple myeloma have changed in the United States over nearly five decades, using population-level data from the SEER database. Multiple myeloma, a cancer of plasma cells, has historically been associated with poor survival outcomes, but treatment options have evolved dramatically over time.

“Aberrant DNA methylation changes lead to abnormal gene expression that contributes to the development and progression of prostate cancer (PCa).”

BUFFALO, NY – April 15, 2026 – A new research paper was published in Volume 17 of Oncotarget on March 31, 2026, titled “Epigenetic dysregulation and biological function of PDX1 in prostate cancer.”

The study was led by first author Tayo A. Adeyika and corresponding author Bernard Kwabi-Addo from Howard University, Washington, DC. The team explored...

“Cancer is an escalating yet neglected health crisis among refugees, migrants, and populations affected by conflict.”

BUFFALO, NY – April 13, 2026 – A new review was published in Volume 17 of Oncotarget on March 31, 2026, titled “Cancer without borders: Policy frameworks for oncology care in humanitarian and conflict settings.”

The study—led by corresponding author Pragnesh Parmar, along with Gunvanti Rathod from AIIMS Bibinagar, Telangana, India—brings together evidence from peer-reviewed...

“Scientific integrity is a crucial component of scholarly publishing.”

BUFFALO, NY – April 10, 2026 – A new editorial perspective was published in Volume 17 of Oncotarget on April 8, 2026, titled “Oncotarget: Past, Present and Future: Trends in the publishing industry.”

Authored by the Scientific Integrity Office at Oncotarget, the editorial comprehensively analyzes the journal’s evolving approach to scientific integrity. It addresses historical challenges in scholarly publishing and...

“Programmed cell death protein-1 (PD-1) and programmed death ligand-1 (PD-L1) inhibitors are widely used in cancer treatment.”

BUFFALO, NY – April 7, 2026 – A new research paper was published in Volume 17 of Oncotarget on March 31, 2026, titled “Efficacy and safety of PD-1/ PD-L1 inhibitors as adjuvants in the treatment of patients with solid cancers: A systematic review and meta-analysis of randomized controlled trials.”

Led by first author Maryam Aleid from Imam Abdulrahman Bin Faisal...

“The findings indicate that the subset of articles focusing on glioma classification that incorporate social factors is relatively scarce in the analyzed data, in contrast to the prominence of epigenetic and imaging factors in the literature.”

BUFFALO, NY – April 6, 2026 – A new review was published in Volume 17 of Oncotarget on March 31, 2026, titled “Bibliometric mapping of glioma classification research through main path, key route, and K-core analyses.”

Led by first and corresponding... The University of Texas MD Anderson Cancer Center, and Juan E. Núñez-Ríos from Universidad Panamericana, the study uses bibliometric network analysis to map how glioma classification research has evolved across clinical, molecular, and social domains. The authors analyzed Web of Science data using direct citation networks and applied main path analysis, key route analysis, and K-core analysis to identify influential papers, critical routes, and densely connected thematic clusters.

“Aramchol and metformin interacted to modestly enhance cell death in PDX UM cells, though this was less than that caused by the combination of aramchol and the multi-kinase inhibitor regorafenib.”

BUFFALO, NY – March 31, 2026 – A new research paper was published in Volume 17 of Oncotarget on March 27, 2026, titled “The SCD1 inhibitor aramchol interacts with regorafenib and metformin to kill tumor cells.”

Led by Michael R. Booth, Laurence Booth, and Jane L. Roberts from Virginia Commonwealth...

“We determined that CREB5 is a key regulator of basal and SCL transcriptional programs and tumor-forming phenotypes in PC.”

BUFFALO, NY – March 24, 2026 – A new research paper was published in Volume 17 of Oncotarget on March 17, 2026, titled “CREB5 regulates stem cell-like transcriptional programs to enhance tumor progression in prostate cancer.”

Led by corresponding authors Emmanuel S. Antonarakis and Justin Hwang from the Department of Medicine and the Masonic Cancer Center at the...

“CAR T-cell therapy has emerged as a particularly promising cancer-specific treatment strategy.”

BUFFALO, NY – February 25, 2026 – A new editorial perspective was published in Volume 17 of Oncotarget on February 20, 2026, titled “CAR-T therapy: Trailblazing CAR(ing) in cancer treatment.”

Led by Uzma Saqib — with corresponding author Krishnan Hajela from the School of Life Sciences, Devi Ahilya Vishwavidyalaya — the perspective reviews recent clinical and translational advances in chimeric...

“By the end of this commentary, it will be evident how a purported ‘general scientific consensus’ may have been artificially engineered by selectively prioritizing studies aligned with the established narrative.”

BUFFALO, NY – February 16, 2026 – A new commentary was published in Volume 17 of Oncotarget on February 6, 2026, titled “Censorship in science: How publishing decisions could have shaped the perceived “general consensus” on COVID-19 vaccine safety and efficacy.”

In this commentary,... Allineare Sanità e Salute” Foundation and the Independent Medical Scientific Commission (CMSi) in Milan, along with colleagues, the authors document a two-year effort to publish a case report and literature review that raised concerns about possible links between mRNA COVID-19 vaccines and rare blood cancers. They argue that editorial decisions, rather than scientific merit, prevented the paper from being published, raising broader questions about transparency and bias in scientific publishing.

“In this article, we assess the risk of developing haematopoietic cancers post-modRNA vaccination based on current scientific literature and explore the reported potential genetic and molecular mechanisms involved in disease pathogenesis.”

BUFFALO, NY – February 11, 2026 – A new case report was published in Volume 17 of Oncotarget on February 6, 2026, titled “Exploring the potential link between mRNA COVID-19 vaccinations and cancer: A case report with a review of haematopoietic...

“Thus, the present hypothesis is that virally encoded proteins such as HPV-E6 or SARS-COV-2 Spike may cooperate in suppressing host defenses including tumor suppressor mechanisms involving p53.”

BUFFALO, NY – January 13, 2026 – A new hypothesis article was published in Oncotarget (Volume 17) on January 3, 2026, titled “Hypothesis: HPV E6 and COVID spike proteins cooperate in targeting tumor suppression by p53.”

Written by Wafik S. El-Deiry, Oncotarget Editor-in-Chief, from The Warren Alpert...

“The collective world-wide evidence from 2020–2025 underscores a biologically plausible connection between COVID-19 vaccination and cancer.”

BUFFALO, NY – January 8, 2026 – A new review was published in Oncotarget (Volume 17) on January 3, 2026, titled “COVID vaccination and post-infection cancer signals: Evaluating patterns and potential biological mechanisms.”

Led by Charlotte Kuperwasser from Tufts University School of Medicine and Oncotarget Editor-in-Chief Wafik S. El-Deiry from The...